- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04815694
THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy (THUNDER2)
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality in locally advanced rectal cancer (LARC) and patients achieving complete response to treatment (CR) usually have a better prognosis in terms of local control (LC), metastases-free survival (MFS) and overall survival (OS).
Recently, an early tumour regression index (ERITCP) was introduced, to predict pathological CR (pCR) after nCRT in LARC patients. In particular, the authors found that the patients with ERITCP <13.1 show a strong response during therapy and have a lower probability to experience distant relapses.
Aim of this clinical trial is to investigate the impact of dose escalation in rectal cancer, identifying the poor responder cases using the ERI index during the course of radiotherapy and increasing the prescribed dose in these patients.
Adopting this boosting protocol, an increase of 10% of CR (clinical and pathological) rate is expected.
For patients enrolled in the trial, chemoradiotherapy (CRT) will be administered using the MRI guided Radiotherapy (MRgRT) machine available in our institution.
If ERI will be inferior than 13.1 the patient will continue the original treatment. Patients with complete clinical response will go through wait and see approach.
If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
The number of cases to be enrolled will be 63. The primary endpoints will be complete response considered as: ypT0N0 in case of Total Mesorectal Excision (TME), ypT0ycN0 in case of LE, ycT0N0 in case of WW; prospective validation of delta radiomics MR-guide Radiotherapy model.
연구 개요
상태
상세 설명
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality in locally advanced rectal cancer (LARC) and patients achieving complete response to treatment (CR) usually have a better prognosis in terms of local control (LC), metastases-free survival (MFS) and overall survival (OS).
Since response to radiotherapy is dose dependent in rectal cancer, dose escalation may lead to higher complete response rates. The possibility to predict patients who will achieve CR before surgery or during nCRT is of crucial importance. Recently, an early tumour regression index (ERITCP) was introduced, to predict pathological CR (pCR) after nCRT in LARC patients. In particular, the authors found that the patients with ERITCP <13.1 show a strong response during therapy and have a lower probability to experience distant relapses.
Aim of this clinical trial is to investigate the impact of dose escalation in rectal cancer, identifying the poor responder cases using the ERI index during the course of radiotherapy and increasing the prescribed dose in these patients.
Adopting this boosting protocol, an increase of 10% of CR (clinical and pathological) rate is expected.
For patients enrolled in the trial, chemoradiotherapy (CRT) will be administered using the MRI guided Radiotherapy (MRgRT) machine available in our institution.
The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on Gross Tumor Volume (GTV) plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil(5-FU) or oral capecitabine will be administered continuously.
A 0.35 Tesla Magnetic Resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated.
If ERI will be inferior than 13.1 the patient will continue the original treatment. Patients with complete clinical response will go through wait and see approach.
If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
After the end of CRT, the clinical response will be evaluated 8-10 weeks using high tesla MR and CT images or FDGPET-CT image 8-10 weeks after the end of nCRT. Surgery will be performed 12-16 weeks after the end of the CRT in case of partial or stable or progression disease, while in case of major or complete clinical response at restaging imaging, a Watch and Wait (W&W) or local excision (LE) approach should be followed. Late toxicity and quality of life (QoL) will be scored at first follow-up (FUP) and at 1 and 2 years of FUP according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 scale, functional scales and QoL questionnaires (LARS and SEXUAL questionnaires, at the start of treatment, after surgery and at 1 and 2 years of FUP), respectively.
The number of cases to be enrolled will be 63: all the patients will be treated at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome. All the cases will be discussed in weekly multidisciplinary tumor board to share the best therapeutic options, both at the diagnosis and at presurgical restaging.
. The primary endpoints will be complete response considered as: ypT0N0 in case of Total Mesorectal Excision (TME), ypT0ycN0 in case of LE, ycT0N0 in case of WW; prospective validation of delta radiomics MR-guide Radiotherapy model.
The secondary endpoints will be:3 years LC, MFS, Disease Free Survival (DFS), OS; R0 resection rate; Tumor Regression Grade (TRG) 1, TRG 2, Neoadjuvant Rectal (NAR) score; Sphincter preservation rate; Organ preservation rate; Rectal and sexual functions.
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Giuditta Chiloiro, MD PhD
- 전화번호: + 39 3934360389
- 이메일: giuditta.chiloiro@policlinicogemelli.it
연구 장소
-
-
-
Roma, 이탈리아, 00168
- 모병
- Fondazione Policlinico Universitario A.Gemelli IRCCS
-
연락하다:
- Margherita Zona
- 전화번호: +39 0630156261
- 이메일: margherita.zona@policlinicogemelli.it
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histological proven adenocarcinoma of the rectum cT2-3, N0-2 or cT4 for anal sphincter involvement N0-2a, M0
- No prior radiotherapy in pelvic region;
- Tumour located between 0 and 15 cm above the anal verge;
- Not mesorectal fascia involvement for tumor
- No extramesorectal nodes involvement
- No extramural venous invasion (EMVI)
- No rectal mucinous adenocarcinoma histology
- No contra-indications for MRI
- Eastern Cooperative Oncology Group (ECOG) 0-1
- Age over 18 years
- Adequate hematological function: granulocyte count > 1500/microl; Hemoglobin level > 10 g/dl; Platelet count > 100000/microl; Alanine Aminotransferase/ aspartate aminotransferase (ALT/AST): 7-45 UI/L;
- No other malignancies in the previous history (except skin and initial cervical cancer);
- Absence of important comorbidities: severe cardiac or coagulative disease, moderate or severe; restrictive/obstructive lung deficit, severe cognitive impairment, moderate and severe renal and hepatic impairment.
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
- Absence of pregnancy or lactating female patients;
- Written informed consent
Exclusion Criteria: not defined
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction >13.1
All patients will be treated on MRgRT, at the second week , patients with an ERI > 13.1 will underwent RT dose intensification on GTV + 3 mm to 60.1 Gy with a Simultaneous Integrated Boost (SIB).
|
The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis.
Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously.
A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT.
At fraction 10, ERI will be calculated.
If ERI will be inferior than 13.1 the patient will continue the original treatment.
If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
|
간섭 없음: LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction < 13.1
All patients will be treated on MRgRT, at the second week , patients with an ERI < 13.1 will underwent standard RT dose of 55Gy on tumor and corresponding mesorectum
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Complete response
기간: 6 months
|
ypT0N0 in case of TME, ypT0ycN0 in case of LE, ycT0N0 in case of WW
|
6 months
|
Prospective validation of delta radiomics MR-guide Radiotherapy model
기간: 6 months
|
correlation between response prediction and clinical or pathological response
|
6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
3 years Local control
기간: 3 years follow up
|
survival outcomes
|
3 years follow up
|
3 years Metastasis Free Survival
기간: 3 years follow up
|
survival outcomes
|
3 years follow up
|
3 years Disease Free Survival
기간: 3 years follow up
|
survival outcomes
|
3 years follow up
|
3 years Overall Survival
기간: 3 years follow up
|
survival outcomes
|
3 years follow up
|
R0 resection rate
기간: 6 months
|
percentage of surgical intervention with negative margins
|
6 months
|
Tumor Regression Grade 2
기간: 6 months
|
surgical outcomes
|
6 months
|
Neoadjuvant rectal (NAR) score
기간: 6 months
|
surgical outcomes
|
6 months
|
Tumor Regression Grade 1
기간: 6 months
|
surgical outcomes
|
6 months
|
Sphincter preservation rate
기간: 6 months
|
percentage of surgical intervention without the positioning of permanent stomia
|
6 months
|
Organ preservation rate
기간: 3 years follow up
|
percentage of patients underwent conservative approaches (WW or EL)
|
3 years follow up
|
Rectal function
기간: 3 years follow up
|
impact of therapy on rectal functions by MSKCC questionnaire (from always to never with 5 items)
|
3 years follow up
|
Sexual function
기간: 3 years follow up
|
impact of therapy on sexual function by IIEF and FSFI questionnaires (from 1 worst to 5 better)
|
3 years follow up
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Giuditta Chiloiro, MD PhD, Fondazione Policlinico Universitario A. Gemelli, IRCCS
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .